Overview
wXELIRI Versus FOLFIRI Regimen in the Treatment of Advanced Colorectal Cancer Patients
Status:
Unknown status
Unknown status
Trial end date:
2015-12-01
2015-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
The aim of this study is to compare weekly-XELIRI(wXELIRI) regimen versus FOLFIRI regimen in the treatment of advanced colorectal cancer patients. The hypothesis is the efficacy of wXELIRI is not less than FOLFIRI with tolerable toxicity.Phase:
Phase 2Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Fudan University
Criteria
Inclusion Criteria:- Second-line treatment for advanced colorectal cancer,irinotecan was not previously
used.
- Age range 18-70 years old
- ECOG performance status 0-1
- Life expectancy of more than 3 months
- Adequate organ function
Exclusion Criteria:
- Previous serious cardiac disease
- History of other malignancies except cured basal cell carcinoma of skin and carcinoma
in-situ of uterine cervix
- Pregnant or lactating women
- chronic inflammatory bowel disease or intestinal obstruction
- Serious uncontrolled diseases and intercurrent infection